Recombinant multi-species SLC39A5 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine SLC39A5 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
The protein encoded by this gene belongs to the ZIP family of zinc transporters that transport zinc into cells from outside, and play a crucial role in controlling intracellular zinc levels. Zinc is an essential cofactor for many enzymes and proteins involved in gene transcription, growth, development and differentiation. Mutations in this gene have been associated with autosomal dominant high myopia (MYP24). Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Sep 2014]
The Alternative Names of target: 1810013D05Rik,2010205A06Rik,LZT-Hs7,MYP24,SLC39A5,Slc39a5,Solute carrier family 39 member 5,ZIP5,Zinc transporter ZIP5,Zip5,Zrt- and Irt-like protein 5 (ZIP-5)
Go
to SLC39A5 products collection
>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-IP1737-Ag-1/ GM-Tg-hg-IP1737-Ag-2 | Human SLC39A5 protein | Human |
| GM-Tg-rg-IP1737-Ag-1/ GM-Tg-rg-IP1737-Ag-2 | Rat SLC39A5 protein | Rat |
| GM-Tg-mg-IP1737-Ag-1/ GM-Tg-mg-IP1737-Ag-2 | Mouse SLC39A5 protein | Mouse |
| GM-Tg-cynog-IP1737-Ag-1/ GM-Tg-cynog-IP1737-Ag-2 | Cynomolgus/Rhesus macaque SLC39A5 protein | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-IP1737-Ag-1/ GM-Tg-felg-IP1737-Ag-2 | Feline SLC39A5 protein | Feline |
| GM-Tg-cang-IP1737-Ag-1/ GM-Tg-cang-IP1737-Ag-2 | Canine SLC39A5 protein | Canine |
| GM-Tg-bovg-IP1737-Ag-1/ GM-Tg-bovg-IP1737-Ag-2 | Bovine SLC39A5 protein | Bovine |
| GM-Tg-equg-IP1737-Ag-1/ GM-Tg-equg-IP1737-Ag-2 | Equine SLC39A5 protein | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. |
GM-Tg-hg-IP1737-Ag-1/ GM-Tg-hg-IP1737-Ag-2;
GM-Tg-rg-IP1737-Ag-1/ GM-Tg-rg-IP1737-Ag-2;
GM-Tg-mg-IP1737-Ag-1/ GM-Tg-mg-IP1737-Ag-2; GM-Tg-cynog-IP1737-Ag-1/ GM-Tg-cynog-IP1737-Ag-2; GM-Tg-felg-IP1737-Ag-1/ GM-Tg-felg-IP1737-Ag-2; GM-Tg-cang-IP1737-Ag-1/ GM-Tg-cang-IP1737-Ag-2; GM-Tg-bovg-IP1737-Ag-1/ GM-Tg-bovg-IP1737-Ag-2; GM-Tg-equg-IP1737-Ag-1/ GM-Tg-equg-IP1737-Ag-2 |
| Products Name | SLC39A5 protein |
| Species | Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine |
| Target Name | SLC39A5 |
| Protein Sub-location | Introcelluar Protein |
| Isotypes | Recombinant protein |
| Expression platform | Mammalian cell |
| Bioactivity validation | Affintiy&bioactivity validated by ELISA, cell culture validated. |
| Tag | His |
| Products description | Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine SLC39A5 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution |
Lyophilized from GM's Protein Stability Buffer2
(PSB2,Confidential Ingredients) or PBS
(pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
About Gmab

GMab, developed by GeneMedi, constitutes an
advanced library of recombinant
monoclonal antibodies, each meticulously
designed to target specific molecular
entities. Leveraging the sophisticated
capabilities of GM’s Taurus™ and LIBRA™
platforms, GMab synthesizes antibodies
characterized by high binding affinity,
exceptional physicochemical stability, and
optimal developability profiles.
Through
expression in mammalian cell lines, GMab has
been established as a paradigmatic
reference antibody. It holds significance in
myriad domains of biological drug
discovery, encompassing cellular cultivation,
innovative assay methodologies,
strategic animal model systematization, in-depth
pharmacokinetic & pharmacodynamic
(PK/PD) modeling, and intricate mechanism of
action (MOA) investigations.